Market News & Trends
TTP Enters Exclusive License Agreement With DiaSorin
TTP plc and DiaSorin have recently signed an exclusive license and technology transfer agreement. DiaSorin will combine its extensive molecular test offering with TTP’s Puckdx…
Evelo Biosciences Announces Biomarker Data Showing Drug is Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases
Evelo Biosciences, Inc. recently announced biomarker data for EDP1815, its lead inflammation product candidate. Interim data from individuals in the ongoing Phase 1b clinical trial…
CN Bio Innovations Raises $9 Million to Strengthen Commercial Development
CN Bio Innovations recently announced it has raised $9 million investment, led by CITIC Securities Investment Co., Ltd., and supported by existing investor CN Innovations…
Bormioli Pharma Speeds Up on Innovation With H-FARM
Fast prototyping and an approach to innovation focused on customer needs are at the heart of the innovation path undertaken by Bormioli Pharma alongside H-FARM.…
Oramed Reports Positive Results in the Final Cohort of its Phase 2b Oral Insulin Trial
Oramed Pharmaceuticals Inc. recently announced positive topline data from the second and final cohort of its Phase 2b trial evaluating the efficacy and safety of its lead…
TrakCel & Ori Biotech Sign Collaboration Agreement
TrakCel and Ori Biotech Ltd recently announced a non-exclusive strategic partnership to achieve supply chain orchestration within closed system manufacturing for the cell and gene therapy sector.…
Theralase Advances Its Pivotal Phase 2 Non-Muscle Invasive Bladder Cancer Study
Theralase Technologies Inc. recently announced that Nova Scotia Health Authority (NSHA) Research Ethics Board (REB) has approved the commencement of a Pivotal Phase 2 Non-Muscle…
Spring Bank Announces New Clinical Collaboration With Roche
Spring Bank Pharmaceuticals, Inc. recently announced a new clinical collaboration with Roche to explore the co-administration of SB 11285, Spring Bank's intravenously (IV)-administered STING (STimulator…
Perrigo & Catalent Announce FDA Approval
Perrigo Company plc and its partner Catalent Pharma Solutions recently announced the US FDA has approved Perrigo’s abbreviated new drug application for generic albuterol sulfate…
FDA Grants IND Approval to Promising Anti-Cancer Agent
Noxopharm recently announced the US FDA has approved the Investigational New Drug (IND) application for Veyonda for combination treatment with doxorubicin in patients with soft…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….